drugset
Drugs / iSCIB1+
last change Aug 2026 re-read 9 days ago

iSCIB1+

Vaccine

Developed for
cutaneous melanoma
Investigated by
Scancell Ltd

Trials 1

today NCT04079166 · Ph 2
20202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04079166 Aug 2019 → Jan 2027 expected cutaneous melanoma Scancell Ltd Active not recruiting Met primary

Press releases naming this drug 11 releases

DateIssuerRelease
2026-08-19 Scancell Ltd Scancell Receives UK MHRA Clinical Trial Authorization for Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma scancell.co.uk ↗
2026-04-28 Scancell Ltd Scancell Receives FDA Fast Track Designation for iSCIB1+ scancell.co.uk ↗
2026-01-26 Scancell Ltd Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma scancell.co.uk ↗
2025-12-09 Scancell Ltd Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ scancell.co.uk ↗
2025-11-07 Scancell Ltd Scancell to present positive Phase 2 data on Immunobody ® iSCIB1+ in late-stage melanoma at SITC 2025 scancell.co.uk ↗
2025-07-22 Scancell Ltd Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody ® iSCIB1+ scancell.co.uk ↗
2025-06-25 Scancell Ltd Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+ scancell.co.uk ↗
2024-09-17 Scancell Ltd Scancell signs strategic partnership with PharmaJet for use of the Stratis ® IM Needle-free delivery System in the development of SCIB1/iSCIB1+ cancer vaccine for Advanced Melanoma scancell.co.uk ↗
2024-07-24 Scancell Ltd Scancell Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3 Registration Clinical Trial scancell.co.uk ↗
2024-03-27 Scancell Ltd First Patient dosed with iSCIB1+ in SCOPE trial scancell.co.uk ↗
2024-01-17 Scancell Ltd MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial scancell.co.uk ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as iSCIB1+ ClinicalTrials.gov intervention name — accepted as the source's own label NCT04079166 ↗
Modality Vaccine “SCIB1 or iSCIB1+ DNA vaccine” NCT04079166 ↗
Route Other “The SCIB1 or iSCIB1+ injection will be given using PharmaJet needle-free injection device systems in the upper arm or upper leg.” NCT04079166 ↗